SHERIDAN, WYOMING – August 26, 2025 – Dentsply Sirona, the world’s largest manufacturer of professional dental products and technologies, has released its 2024 Sustainability Report, highlighting significant achievements across environmental, social, and governance pillars. The company surpassed several of its 2025 targets ahead of schedule and introduced a new long-term commitment: achieving 100% recyclable packaging by 2030.

Advancing Sustainability Through the BEYOND Strategy

SHERIDAN, WYOMING – August 26, 2025 – Dentsply Sirona has reinforced its commitment to widening access to oral healthcare through its fourth annual Miles for Smiles charity walk, raising £18,000 to support underserved communities across the UK and Ireland. The initiative, part of the company’s broader BEYOND: Taking Action for a Brighter World sustainability program, reflects the dental technology leader’s continued alignment of corporate responsibility with community health needs.

Walking for Change in Oral Health

SHERIDAN, WYOMING – August 26, 2025 – Dentsply Sirona is intensifying its commitment to digital orthodontics with the launch of a global educational webinar series built around its SureSmile platform. The initiative aims to help orthodontists and dental teams integrate advanced digital workflows into everyday practice, driving improvements in treatment planning, patient outcomes, and practice efficiency.

Advancing Clinical Education in Digital Orthodontics

SHERIDAN, WYOMING – August 26, 2025 – Dentsply Sirona, the FDI World Dental Federation (FDI), and Smile Train have expanded their joint cleft care education program, introducing multilingual access to their digital training platform and new workflow videos aimed at improving cleft treatment globally. The initiative, timed with Cleft Awareness Month, underscores a strategic push to equip dental professionals with advanced tools, protocols, and training to address one of the most common congenital conditions affecting children worldwide.

SHERIDAN, WYOMING – August 12, 2025 – Eli Lilly’s Phase III results for its next-generation oral GLP-1 therapy, orforglipron, have energized the already competitive obesity drug market, sparking renewed focus on oral weight-loss candidates poised to challenge the injectable-dominated landscape. While Lilly’s data confirmed significant efficacy, industry analysts see room for competitors to gain ground with differentiated mechanisms, dosing advantages, and manufacturing scalability.

SHERIDAN, WYOMING – August 12, 2025 – A wave of safety concerns surrounding adeno-associated virus (AAV) gene therapy has hit the biotechnology sector following multiple patient deaths linked to Sarepta Therapeutics’ platform. While some stakeholders push for urgent refinements to the decades-old technology, others are accelerating work on alternative delivery systems that could reshape the future of genetic medicine.

SHERIDAN, WYOMING – August 12, 2025 – The Department of Health and Human Services (HHS) is facing fresh turbulence after the abrupt dismissal of Gray Delany, the lead implementor of the Make America Healthy Again (MAHA) initiative. The move comes just days after Health Secretary Robert F. Kennedy Jr. terminated 22 mRNA vaccine contracts worth a combined $500 million, triggering intense debate across the biomedical and public health sectors.